Structure functional insights into calcium binding during the activation of coagulation factor XIII A by Singh, S et al.
1Scientific RepoRtS |         (2019) 9:11324  | https://doi.org/10.1038/s41598-019-47815-z
www.nature.com/scientificreports
Structure functional insights into  
calcium binding during the activation 
of coagulation factor Xiii A
Sneha Singh1, Johannes Dodt  2, peter Volkers2, emma Hethershaw  3, Helen philippou  3, 
Vytautus ivaskevicius1, Diana imhof  4, Johannes oldenburg1 & Arijit Biswas1
the dimeric fXiii-A2, a pro-transglutaminase is the catalytic part of the heterotetrameric coagulation 
fXiii-A2B2 complex that upon activation by calcium binding/thrombin cleavage covalently cross-links 
preformed fibrin clots protecting them from premature fibrinolysis. Our study characterizes the recently 
disclosed three calcium binding sites of fXiii-A concerning evolution, mutual crosstalk, thermodynamic 
activation profile, substrate binding, and interaction with other similarly charged ions. We demonstrate 
unique structural aspects within FXIII-A calcium binding sites that give rise to functional differences 
making FXIII unique from other transglutaminases. The first calcium binding site showed an 
antagonistic relationship towards the other two. The thermodynamic profile of calcium/thrombin-
induced FXIII-A activation explains the role of bulk solvent in transitioning its zymogenic dimeric form 
to an activated monomeric form. We also explain the indirect effect of solvent ion concentration on 
FXIII-A activation. Our study suggests FXIII-A calcium binding sites could be putative pharmacologically 
targetable regions.
Calcium ions (Ca2+) play a major role in the tight regulation of coagulation cascade that is paramount in the 
maintenance of hemostasis1,2. Other than platelet activation, calcium ions are responsible for complete activa-
tion of several coagulation factors, including coagulation Factor XIII (FXIII)3. FXIII is responsible for covalently 
cross-linking preformed fibrin clots preventing their premature fibrinolysis, by maintaining the clot architec-
ture and strength. FXIII circulates in plasma as a heterotetrameric pro-transglutaminase (pFXIII), complex 
FXIII-A2B2 composed of dimeric subunits of catalytic FXIII-A and protective/regulatory FXIII-B4–7. Although 
the catalytic FXIII-A subunit bears several structural and sequence similarities with other transglutaminases, 
it is also unique in specific aspects8. Unlike other members of the transglutaminase family, FXIII-A is the only 
molecule activated by a combination of calcium binding and proteolytic thrombin cleavage of an N –terminal 
37-amino acid region [activation peptide (FXIII-AP)]. Additionally, it is also the only transglutaminase whose 
functional molecule is a complex, unlike other transglutaminases that are monomeric. FXIII-A, like all other 
transglutaminases belongs to a category of calcium-binding proteins that lacks EF-hand motif, a typical struc-
tural helix-loop-helix topology commonly found in calcium binding proteins9. Transglutaminases are believed to 
have evolved from an ancient cysteine protease in bacteria10. The microbial transglutaminase though has evolved 
divergently from the eukaryotic transglutaminases11. Although calcium-binding is common to the activation 
pathway of all transglutaminases, different members of the transglutaminase family show additional regulatory/
functional features in their activation mechanisms, despite sharing a structural and sequential similarity. For 
instance, Transglutaminase 2 (TG2) has multiple regulatory features in addition to calcium binding like vicinal 
disulfide bonds and GTP/GDP binding which in combination control the activity status of the protein at differ-
ent ionic conditions9. The FXIII-A subunit is a structurally well-characterized protein with several zymogenic 
crystal structures, in ion-bound (to different cations; PDB IDs: 1ggu, 1ggy, 1qrk) and unbound states (PDB ID: 
1fie, 1f13) present in the protein structure database12–14. The recent disclosure of the non-proteolytically activated 
form of FXIII-A (FXIII-A*) (PDB ID: 4kty) has shown the presence of three calcium binding sites in FXIII-A15. 
The first FXIII-A calcium binding site (Cab1) involves the residues Ala457, Asn 436, Glu 485 and Glu 490, the 
1Institute of Experimental Hematology and Transfusion medicine, University Hospital of Bonn, Bonn, 53127, 
Germany. 2Paul-Ehrlich Institute, Langen, 63225, Germany. 3Discovery and Translational Science Department, 
University of Leeds, Leeds, LS29JT, United Kingdom. 4Pharmaceutical Biochemistry and Bioanalytics, 
Pharmaceutical Institute, University of Bonn, An der Immenburg 4, Bonn, 53121, Germany. Correspondence and 
requests for materials should be addressed to A.B. (email: arijit.biswas@ukb.uni-bonn.de)
Received: 12 October 2018
Accepted: 24 July 2019
Published: xx xx xxxx
open
2Scientific RepoRtS |         (2019) 9:11324  | https://doi.org/10.1038/s41598-019-47815-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
second calcium binding site (Cab2) uses the residues Asp 351, Gln 459, Asn 347, Asp 349, and Asp 343 and the 
third calcium binding site (Cab3) coordinates the residues Asp 271, Asn 267, Asp 270 and Ala 26415. In our ear-
lier study, while explaining the concerted model of FXIII activation we had demonstrated in silico that the first 
calcium binding site (Cab1) that is usually observed constitutively coordinated in specific zymogenic FXIII-A 
crystal structures (E.g. PDB ID: 1ggu), actually lays a stabilizing influence on the zymogenic form12,16. We also 
showed that its transient disruption upon thrombin-mediated FXIII-AP cleavage and simultaneous coordination 
of the other two calcium binding sites (Cab2, Cab3) is essential for the conformational activation of zymogenic 
FXIII-A. Cellular FXIII (cFXIII) that is inaccessible to plasma thrombin requires high supra-physiological levels 
of calcium or a combination of high sodium and physiological calcium for non-proteolytic activation. Hence, 
Cab1 as a zymogenic constraint acts antagonistically to the other two calcium binding sites keeping the molecule 
inactive intracellularly in the absence of thrombin unless provoked by high ion concentrations16.
In continuation of our preliminary work and observations, our current study takes a deeper look into the 
calcium binding sites of FXIII-A. We investigate how these sites contribute to the functional evolution of FXIII 
molecule as a unique protein in the transglutaminase family. We characterize the three FXIII-A calcium bind-
ing sites concerning their evolution, mutual crosstalk, and effect on FXIII-A thermodynamic profile, substrate 
binding and interaction with other similarly charged ions. The FXIII-A calcium binding sites show a high degree 
of conservation within transglutaminases, but at the same time, they also possess unique spatial and structural 
features that differentiate FXIII-A as a unique molecule amongst transglutaminases. Our results confirm that sat-
uration of the first calcium-binding site lays a zymogenic constraint that resists the activation of FXIII-A, as was 
hypothesized in our earlier work16. The thermodynamic profile of FXIII-A activation observed during increased 
calcium binding reiterates recent observations that calcium binding to FXIII-A results in major conformational 
changes leading up to the dissociation of the FXIII-A2 dimer during activation to a monomeric activated FXIII-A 
(FXIII-A*) form. Using all atoms MD simulations of FXIII-A and its core domain under different ionic concen-
trations we show that apart from coordination with charged residues, the mere presence of cations can also bring 
about subtle changes in the structure of FXIII-A by altering the surface electrostatics. The alteration of FXIII-A 
subunit´s surface electrostatics can, in the long term, influence the activation status of the molecule in different 
ionic conditions.
Results
Calcium binding site residues on FXIII-A molecule are highly conserved. Within the multiple 
alignments of FXIII-A with other known transglutaminases, all three calcium binding site residues showed a 
high degree of conservation [Average generalized conservation score: 9 (range = 8–9)] (Fig. 1a). However, several 
variant substitutions observed in the multiple alignments corresponding to these residues, including few (Cab1 
residues E485 and E490) in which the substitution was to an oppositely charged residue. These residues occur in 
a semi-conserved region with the conservation status varying between high to low conservation between alter-
nating residues (Fig. 1b). The structural alignment of the crystal structures of FXIII-A, TG2, TG3 and threaded 
models of TG1, TG4, TG5, TG6, TG7 shows proper domain-wise alignment with the average RMSD of 1.2 Å 
(Range: 0.5–1.71 Å) (Fig. 1c). FXIII-A shows the closest structural similarity with TG1 (0.5 Å RMSD) (Fig. 1c,d). 
The three calcium binding sites were in spatially similar locations in the aligned structures (Fig. 1c). However, 
the distance between their backbone atoms as well as the orientation of the side chain residues differed between 
transglutaminases (Fig. 1e).
Biochemical endpoint FXIII activity assays reveal that calcium binding influences the forma-
tion of substrate binding pockets on FXIII-A molecule. Biochemical endpoint FXIII activity assays, 
which primarily evaluate transglutaminase cross-linking function when evaluated for the FXIII-A calcium bind-
ing mutants showed most of them lacking in cross-linking ability. The photometric assay, combined with anti-
genic determination revealed that the specific activity of FXIII-A was reduced in all mutants expressed when 
compared with the wild type (0.02 ± 0.001 IU/mg/mL). The mutant N347D reported the lowest specific activity 
(0.00087 ± 0.0001 IU/mg/mL; p < 0.0001) (Fig. 2a). Pentylamine incorporation assay also reported low levels 
of interpolated FXIII-A activity (incorporated/crosslinked substrate in µg/mL) in all mutants except N267K 
(2.17 ± 0.58 µg/ml) in which it was non-significantly elevated when compared to the Wild type (1.92 ± 0.31 µg/
mL; p = 0.42) (Fig. 2b). The lowest interpolated FXIII-A concentration was observed for the mutant D271K 
(0.32 ± 0.04 µg/mL; p < 0.0001). Similar to the Pentylamine incorporation assay, average interpolated active 
FXIII-A* concentration from the α-2-antiplasmin incorporation assay using fibrin as a substrate (in µg/mL) was 
also reduced for all mutants when compared with the wild type (8.97 ± 0.83 µg/mL), except in mutant A457D 
which showed non-significantly elevated levels (9.40 ± 0.02 µg/mL; p = 0.09) (Fig. 2c). One mutation from the 
Cab3 (D271K) and two from Cab2 (N347D, Q349D) showed no detectable α-2-antiplasmin incorporation (i.e. 
<1.25 µg/mL). The putative substrate binding regions corresponding to fibrinogen substrate (in cyan) outnumber 
those of substrates α-2-antiplasmin (in magenta) and BAPA [5-(Biotinamido) pentylamine; PubChem ID: CID 
83906] (in yellow) (Fig. 2d). This difference in putative binding sites is expected considering the relative sizes 
of these substrates, fibrinogen being the largest and BAPA the smallest (Supplementary Fig. 1). While some of 
these regions lie close to the active site, others are far from it and most likely have an allosteric role in substrate 
binding. Interestingly, fibrinogen substrate binding regions cover almost all calcium binding sites, but those of 
α-2-antiplasmin appear closer to Cab2 while those of BAPA lie closer to Cab3 (Fig. 2d).
Real-time monitoring of fXiii-A* generation confirms that Cab1 is a zymogenic constraint on 
FXIII-A. The FXIII-A* generation assay which tracks the rate of FXIII-A* generation real-time reported dif-
ferences from the endpoint assay for the calcium binding site mutants in several of the parameters derived from 
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its curve (Fig. 3, Supplementary Fig. 2). The calcium binding site mutations have been designed keeping in mind 
our earlier formulated and reported hypothesis that making the Cab1 more positive will result in acceleration of 
FXIII-A activation while doing the same to Cab2 and Cab3 will impede activation and vice-versa (Fig. 3a)16. The 
Cab1 mutant E490K reported an almost ~2.5x times higher rate of FXIII-A* generation (µ) (217.36 ± 54.74 R.F.U./
min) than the wild type rFXIII-A (83.17 ± 21.88 R.F.U./min) (Fig. 3b). The other Cab1 mutant A457D reported 
a lower rate of FXIII-A* generation but not significantly, so (64.34 ± 21.36 R.F.U./min). One mutation from the 
Cab3 (D271K) and two from Cab2 (N347D, Q349D) revealed a highly significant decrease in the rate of FXIII-A* 
generation/activation (Fig. 3b). The parameter tmax (time taken to reach the maximal rate µ) revealed a good 
inverse correlation with the rate of FXIII-A* generation or µ, with the lowest value for tmax consistent with 
the highest µ observed for Cab1 mutant E490K (Fig. 3c). The parameter tlag (time required for the activation 
of FXIII-A by thrombin) was elevated for all mutants when compared to the wild type rFXIII-A except for the 
Cab2 mutant Q349D, which reported lower but non-significant values (6.90 ± 2.69 min) (Fig. 3d). The thrombin 
resistant mutant FXIII-A-R38A showed an exponential increase in the rate of FXIII-A* generation when the assay 
was performed with increasing levels of calcium concentration (Supplementary Fig. 3). However, it is noticeable 
that the exponential trend-line is a better fit at levels above 20 mM calcium, suggesting that this concentration 
might be rate-limiting for non-proteolytic activation of FXIII-A. The maximal rate of FXIII-A* generation of the 
corresponding standard plasma was observed to be 158.8 R.F.U./min.
Figure 1. Conservation of calcium binding sites in Transglutaminases with respect to FXIII-A. Panel a 
tabulates the conservation results generated for the FXIII-A amino acid sequence input (Uniprot ID: P00488; 
F13A_HUMAN) on the Consurf server. Abbreviations: NCS: Normalized conservation score, GCS: Generalized 
conservation score. Panel b illustrates the actual alignment generated as output on the Consurf server for the 
FXIII-A subunit sequence input. The highly conserved residues are shaded in blue. Arrows indicate the binding 
site residues mutated in this study. Panel c shows a structural alignment of all seven human Transglutaminases 
i.e. of three crystal structures TG2, TG3 and FXIII-A and threaded models for the remaining four 
transglutaminases. The structures are depicted in ribbon format. The inset image shows the spatial alignment 
of the calcium binding site residues of all transglutaminases as stick models. The different transglutaminases 
are colored differently. Panel d shows a structural similarity tree generated from the structural alignment on 
Panel c. The distances on the tree represented by the delta QH value is proportional to the dissimilarity between 
two structures i.e. the farther two structures are there on the tree, the more structurally unlike they are. Panel e 
shows the structural alignment of only three human Transglutaminases with biophysical crystal structures i.e. 
TG2, TG3 and FXIII-A. The inset diagram the spatial alignment of the calcium binding site residues as stick 
models of the three human transglutaminases. The structures are depicted in ribbon format with TG2, TG3 and 
FXIII colored yellow, magenta and cyan respectively. The bidirectional arrows represent the C-α backbone atom 
distances between the D345 and D351 residue (FXIII; cyan), E306 and E314 residue (TG2; yellow), and D303 
and D309 residue (TG3; magenta).
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Simulation of FXIII-A at different ionic concentrations reveals that ancillary ions play a role 
in bringing the molecule to a pre-activated state by altering surface electrostatics. Molecular 
dynamic simulations of FXIII-A and its core domain performed under different concentrations of calcium and 
sodium shed some light into the activation behavior of FXIII-A when exposed to binding (calcium) as well as 
non-binding (ancillary; sodium) ions. Simulations for the full zymogenic FXIII-A crystal structure (source PDB 
ID: 1f13) equilibrated close to the 30 ns time point between 1–1.5 Å RMSDs for both physiological and high 
sodium ion concentrations. The core domain simulations, on the other hand, equilibrated faster closer to 20 ns 
and between 1.5–3.5 Å RMSDs, depending on the calcium ion concentration of the simulation (Supplementary 
Fig. 4). All simulation trajectories in the production phase i.e., only post equilibrations were considered relevant 
and analyzed. Simulations performed at different ion concentrations for both the full zymogenic FXIII-A sub-
unit as well as the core domain did not demonstrate any drastic changes in overall structure post equilibration 
(Fig. 4a). The lack of any significant differences in overall structure is expected owing to the relative short time 
scale of simulation (100 ns; consistent conformational changes on a large scale i.e., >5 Å will require runs close 
to µseconds which considering the size of our simulations, i.e., 85,000–500,000 atoms would be computationally 
too expensive for this study). However, a noticeable change in the surface electrostatic pattern/distribution was 
observed (Fig. 4b). Increasing cation concentrations in different simulations resulted in an increasing spread of 
positive potential over the surface of the simulated structures (Fig. 4b). This change was also coupled to change 
in RINs within these structures (Fig. 4a,b). The overall impact was that the changes in RINs within these struc-
tures were bringing about a change in their secondary structure profile. However, the changes in the secondary 
structure profile were very subtle and not amply visible on the secondary structure profile, most likely owing to 
the shortness of the simulation runs.
Figure 2. Effect of rFXIII-A calcium binding site mutants on its specific activity and substrate specificity. 
Panels a, b and c represent comparative bar graphs for Specific activity of intracellular lysates (wild type and 
variant) based on Photometric assay, interpolated FXIII-A activity based on Pentylamine incorporation assay 
and α-2 antiplasmin incorporation assay, respectively. In the event a variant is significantly different than 
the wild type, it is marked with a star (*) sign on top of the corresponding bar. Statistical significance is set at 
p < 0.05. Experiments were performed in duplicates, thrice (N = 6). Panel d shows the putative fibrinogen, 
α-2 antiplasmin and BAPA binding site residues on zymogenic FXIII-A monomeric and activated monomeric 
FXIII-A* structures along with two intermediate transition state structures. The structure backbone is depicted 
in grey colored ribbon format. The putative binding site region backbones are colored cyan for fibrinogen, 
yellow for BAPA and magenta for α-2 antiplasmin. The three calcium binding sites are also depicted on all four 
structures as stick models colored red (Cab1), blue (Cab2) and green (Cab3) respectively.
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thermodynamic analyses of calcium binding to fXiii-A suggests that fXiii-A activation is a 
stepwise process resulting in its monomerization upon activation. Our ITC thermodynamic pro-
files suggest that at varying c-values [i.e., ratio of the concentration of ligand in the injection (calcium) to the 
concentration of macromolecule in the cell (rFXIII-A2)]; the binding profile of calcium to rFXIII-A2 is different. 
Our thermodynamic profiles reveal that the binding of calcium is not a simple protein-ligand association; rather, 
it is a complicated mechanism involving conformational changes coupled with domain movement and subunit 
dissociation taking place simultaneously. Amongst a range of c-values tested, a c-value of 20 yielded an interest-
ing thermodynamic profile representative of all aspects of calcium binding and subsequent rFXIII-A activation 
(Fig. 5). Other c-values either yielded no binding or were low on informational content (Supplementary Figs 5 
and 6, for c-value 25,000). Fitting exercises performed in Affinimeter, following a custom model binding approach 
(see Method section). The thermodynamic activation profile is divided into three events. The titrations involving 
Figure 3. Results of FXIII-A* generation assay for rFXIII-A calcium binding site mutants. Panel a explains 
the principle underlying different rFXIII-A calcium binding site mutants generated in this study. It depicts 
the conformational transformation between the zymogenic and activated FXIII-A crystal structures. Both 
structures are depicted as grey ball and stick models. The first calcium binding site (Cab1) residues are 
depicted as red ball models on the zymogenic FXIII-A crystal structure because the coordination of this site 
is a zymogenic constraint. The second and third calcium binding site (Cab2 and Cab3) are depicted as blue 
and green ball models respectively on the activated FXIII-A* crystal structure. Below both these structures, 
the mutants generated for this study are listed with arrows indicating the anticipated structure favored by each 
of this mutant as per our hypothesis. Panels b, c and d depict the comparative bar graphs corresponding to 
three major parameters (μ, tmax and tlag) obtained from the FXIII-A* generation assay. In the event a variant 
is significantly different than the wild type, it is marked with a star (*) sign on top of the corresponding bar. 
Statistical significance is set at p < 0.05. Experiments were performed in in duplicates, thrice (N = 6). Please 
note, FXIII-A* generation data for the mutants D271K and N347D show very low activity and a fit of the data to 
the model revealed no valid estimates.
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c-value = 20 (1.25 mM rFXIII-A2 (sample cell) and 25 mM calcium (syringe: CaCl2)), showed endothermic val-
ues with ∆H = 1.35 kJ/mol for the first binding event (M1 + A1 ↔ M1A1,kD1 100 µM)17. In the second binding 
event (M1A1 + A1 ↔ M1A2, kD2 2.7 mM), calcium binding affinity was lower with ∆H = −3.58 ± 0.08 kJ/mol 
(exothermic). The third and final binding event (M1A2 + A1 ↔ M1A3, kD3 = 72.5 mM), calcium affinity was also 
low with ∆H = −41.84 kJ/mol (exothermic) (Global- χ2 = 0.11). The overall analysis suggests that all three reac-
tion components involve entropy changes (see thermal footprints, Fig. 5d) with ∆∆S (change in entropy) get-
ting more positive with the binding event taking place. All the three events were spontaneous (∆G < 0) at given 
conditions (temperature T = 30 °C). The first event involving the saturation of Cab2 and transient disruption of 
Cab1 following its binding is an entropy-driven event. The second event involving saturation of Cab2 and solvent 
exposure of the dimeric interface is also driven by entropy. The third event i.e., the saturation of Cab3 resulting 
in dimer disruption, is an enthalpy-driven event different than the first two events. The contribution of individ-
ual species towards the thermogram (Fig. 5c), suggests that the intermediate M1A1 (Cab1 saturated rFXIII-A2 
with FXIII-AP cleaved), is high energy unstable intermediate which undergoes heat absorption (endothermic). 
For data evaluation, a proper fit was achieved in Affinimeter. The data fitting depicted in Fig. 5b represents the 
raw data and fitting based on the sequential binding site model of Origin software (with fixed parameter Kd and 
∆H) (also see Supplementary Fig. 5, for fitting curves obtained from Affinimeter). Blank measurements were 
made for thrombin and FXIII-A in the cell, against buffer to rule out the heat changes due to ion hydration. The 
absence of any heat changes in the blank ITC experiment overrides the possibility that the interpretations made 
here may be an effect of the heat of dilution. The data obtained after fitting exercises in Affinimeter following the 
stoichiometric equilibria model suggests significant enthalpy-entropy compensation involved in the binding of 
calcium to rFXIII-A2, to reach full saturation (thermal footprints, Fig. 5d, range of ∆∆G is much smaller than 
their associated changes in ∆∆H & ∆∆S)18,19.
Discussion
the structural and functional conservation of calcium binding sites within the transglutam-
inase family. Allosteric changes resulting from ion coordination of amino acid side chains often have fas-
cinating functional implications20. Such coordination when they result in changes crucial to the catalytic cycle 
of a protein becomes a conserved trait across the evolutionary chain. The binding of calcium to FXIII and its 
paralogues and orthologues across the phylogenetic tree is a property that not only initiates the events of their 
catalytic cycle but in effect is responsible for all downstream changes. That includes dictating the rate of gener-
ation of the activated species, exposure of the catalytic triad, to the formation of substrate binding pockets and 
eventually (in the case of FXIII) formation of a monomeric activated form16,21. A closer look into the multiple 
sequence alignment of calcium binding site residues reveals that the negatively charged amino acids capable of 
side chain coordination are highly conserved (Fig. 1a). These residues usually occur in a neighborhood cluster 
of similarly charged amino acids which offsets the potentially deleterious effect of any unfavorable substitution 
Figure 4. Effect of calcium and sodium on the structure of FXIII-A. Upper parts of panels a and b represent 
the simulation snapshots of full length FXIII-A molecule and FXIII-A core domain post 100 ns of simulation 
in different sodium and calcium concentrations respectively as indicated. The simulation snapshot structures 
are depicted by their molecular surface view with the electrostatic potential (Red: Negative, Blue: Positive) 
superimposed on it. Below the simulation snapshots in both panels are the Residue interaction network (RIN) 
or the inter-residue interaction chart extracted from the Ring 2.0 server by submitting to it the post 100 ns 
simulation snapshot as a PDB file under default server conditions. Lowermost section of both panels is the 
Secondary structure profile for the entire 100 ns of simulation plotted for the entire length of the molecule. The 
colour code for the secondary structure profile is the following: Coil: Red, Strand: Green, Helix: Blue, Turn: 
Black.
7Scientific RepoRtS |         (2019) 9:11324  | https://doi.org/10.1038/s41598-019-47815-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
at the coordinated residue by overtaking its coordination function (Fig. 1b). Therefore in spite of the high degree 
of conservation amongst calcium binding site residue, substituted variants including substitution to positively 
charged residues are observed in the conservation-related multiple sequence alignment. The existing literature 
indicates that amongst transglutaminases (EC 2.3.2.13) there can be as many as six high to low-affinity calcium 
binding sites. However, multiple alignments of a fairly large cohort of non-redundant sequences across the trans-
glutaminase enzyme family indicate that at least in eukaryotic transglutaminases, three of these are of almost 
universal occurrence22. Unavailability of detailed structural information and the evolution of a compensatory 
regulatory motif might be the reason why some of these sites are not yet reported or not present in a few mem-
bers of transglutaminase (TGase) family23. Amongst the structurally best-characterized transglutaminases, i.e., 
TG2, FXIII-A, and TG3; TG2 has additional regulatory mechanism23. These are the GTP/GDP switch (effective 
intracellular, at low calcium levels) and the vicinal disulfide bonds (effective extracellular, at high calcium levels). 
These additional regulatory mechanisms explain the need of six calcium binding sites in TG2 to induce the con-
formational pull needed for overall activation of the molecule (which therefore would be higher than FXIII or 
TG3). The enzymes, FXIII and TG3 differ from TG2 concerning calcium binding (Fig. 1c) because unlike TG2, 
both proteins have one constitutively bound calcium which confers their zymogenic forms stability while the 
other two sites are structurally shielded in the zymogenic state till they are functionally required. The TG3 is an 
inactive 77 kDa zymogen that must be cleaved into a 50 kDa N-terminal fragment containing the active site and 
a 27 kDa C-terminal fragment, which remains associated with the mature enzyme24. The zymogen binds a single 
Figure 5. Calcium binding to rFXIII-A2 studied by ITC. Panel a. Equation depicting the stoichiometric binding 
equilibrium model, followed for the analysis of data derived from ITC (Model was generated in Affinimeter 
using model builder approach). Panel b. Titration of 1.25 mM rFXIII-A2, with 25 mM CaCl2 (c-value = 20). 
Upper image of this panel is the raw data depicting the heat change upon each injection; lower image in this 
panel is the normalized data, with integrated heat change plotted against the concentration ratio of calcium 
vs rFXIII-A2. Solid black line represents the corresponding fit obtained in Origin software using sequential 
binding mode, with n = 3. All heat changes are plotted after subtraction of reference titration (no rFXIII-A2 in 
sample cell vs. 25 mM CaCl2 in the presence of thrombin, at same conditions) Panels c, d and e are based on 
evaluation performed on Affinimeter (see Supplementary Fig. 5 for corresponding fit curves). Panel c depicts 
the contribution of individual species, generated during a sequential binding of calcium to FXIII-A (based on 
earlier observations19 and as participants of the Stoichiometric equilibria here (Panel A)), towards the binding 
isotherm. Panel d is the comparative heat signatures, or the thermal footprints obtained at each binding event 
following the equation ∆G = ∆H - T∆S (2nd Law of Thermodynamics); explaining the three thermodynamic 
events, and their corresponding changes in free energy (∆G), entropy (-T∆S) and enthalpy (∆H) (for the 
corresponding data obtained at c-value = 25,000 please refer to the Supplementary Fig. 6). Panel e is table 
representing event-wise changes in enthalpy (∆H), in kJ/mol, and corresponding change in binding affinity of 
calcium ions towards FXIII-A in all three corresponding events as per the stoichiometric equilibria model.
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calcium ion with high affinity (Kd = 0.3 µM)25. Upon cleavage, two additional ion binding sites with an average 
dissociation constant of 4 μM become available. Calcium coordination by Asp324 induces the movement of a loop 
region, enabling substrate access to the active site. The FXIII-A molecule, similar to TG1, has been reported in 
certain crystal structures to be bound constitutively to a single calcium ion at Cab112. The activation events initi-
ated by thrombin-mediated cleavage of its N-terminal activation peptide expose the other two calcium binding 
sites to coordinate, resulting in a series of conformational changes involving the formation of substrate binding 
pockets and ultimately exposing the catalytic triad16. Therefore, while retaining these three highly conserved 
calcium binding sites, these enzymes have functionally evolved differently to use these sites in a way that is best 
suited to their physiological milieu. Amongst FXIII-A and TG3, the one calcium binding site that imparts the 
zymogenic restraint differs. Sequence-wise and structurally, the constitutively bound zymogenic calcium binding 
site in FXIII-A (Cab1) effectively aligns with the activating/regulatory calcium binding site in TG3 (Cab3 in TG3) 
and vice versa. The spatial position of all three calcium binding sites in all transglutaminase structures is similar 
(Fig. 1c). However, the orientation of the binding site residue side chains varies along with their inter-atomic 
distance, between transglutaminases. As an example, the distance between the C-α backbone atoms of the Cab2 
binding site residues (FXIII-A calcium binding site nomenclature) is shown in Fig. 1e. The C-α backbone inter-
atomic distances are similar for TG3 and FXIII-A (11 and 12 Å respectively) with TG2 (15 Å) being different. The 
difference in inter-atomic distances is reflected in the similarity of the coordination pattern, as mentioned earlier 
for these proteins. Based on a structural relationship tree, we find that TG1 is more similar to FXIII-A than any 
other transglutaminase, which also is true evolutionarily since these two proteins are closely related (Fig. 1d). 
The overall structural similarity is reflected in similarity in calcium binding sites as well since the binding site 
residues align better between FXIII-A and TG1 than with TG7 which is far away on the structural tree from FXIII 
(Fig. 1d; Supplementary Fig. 7). Transglutaminases at a prokaryotic level have evolved from ancient cysteine 
proteases (papain-like thiol proteases); and several microbial transglutaminases, as well as cysteine proteases, 
show a dependency on calcium for the regulation of activity. Therefore one might assume that the mammalian 
FXIII calcium-binding sites have evolved from ancestral calcium binding sites in microbial transglutaminases and 
cysteine proteases22. However, microbial transglutaminases themselves have evolved divergently to eukaryotic 
transglutaminases. The only structurally fully characterized primitive transglutaminase from Streptoverticllium 
mobaraense (PDB ID: 1iu4) does not even show calcium dependence. Also the structural alignment of microbial 
cysteine protease that do show calcium dependence/binding like LapG (Legionella pneumophila) with the core 
domain of FXIII-A subunit shows no similarity in the spatial location of the calcium binding sites, even though 
the two structures align well with respect to sharing the conserved 4-sheet one-helix fold (Supplementary Fig. 8) 
of transglutaminases. All the above observations lead us to conclude that calcium binding sites in eukaryotic 
transglutaminases including FXIII have evolved divergently and have no evolutionary connection to the calcium 
binding sites in microbial transglutaminases or ancestral cysteine proteases.
cross-talk of fXiii calcium binding sites and their importance in the development of substrate 
binding pockets. In our earlier in silico study, we had presented the possibility that coordination of Cab1 of 
FXIII-A molecule stabilizes the zymogenic form of FXIII-A16. Our results from the generation assay support our 
hypothesis that the Cab1 binding site is a zymogenic constraint and that its transient disruption caused by cal-
cium coordination at Cab2 post thrombin-mediated FXIII-AP cleavage is the rate determining step for FXIII-A 
activation (Fig. 3). The unique role of Cab1 is confirmed by the accelerated rate of activation of the molecule 
upon disrupting the calcium coordinating shells of Cab1 (E490K), disengaging calcium binding to Cab1, in the 
presence of an intact Cab2 (Fig. 3). The mutation (E490K) which introduces an additional positive charge within 
Cab1 has the same effect as the coordination at Cab2 i.e., it prevents the calcium binding at Cab1 thereby releasing 
this variant molecule from the zymogenic constraint imposed by Cab1, and it is then reflected in a significantly 
higher rate of FXIII-A* generation than the wild type as well as the other Cab variants (Fig. 3b). The endpoint 
assays, however, record lower activity of this mutant compared to the wild type (Fig. 2a–c), which re-emphasizes 
the fact that the rate of activation of the enzyme and the direct substrate turn-over are independent properties of 
the FXIII mediated catalysis especially when it comes to mutations/variants close to substrate binding or active 
site. The strong differences between the generation assay parameters and the endpoint assays (like photometric 
assay) indicate that the isopeptidase activity on which the generation assay is based26 and the transglutaminase 
crosslinking activity should not be considered synonymous especially when dealing with mutants. Our study is in 
close agreement with an earlier report that suggests that by mutating hydrophobic residues around the active site 
it is possible to have transglutaminase variants that are deficient in crosslinking activity but have normal or raised 
isopeptidase activity24. Certain calcium binding mutants (like E490K) therefore influence cross-linking activity 
negatively by altering the substrate binding sites of the acceptor or donor (cross-linking activity as also mentioned 
in the methods section is a two-step ping pong reaction). However, this same mutation shows a raised isopep-
tidase activity because by releasing the zymogenic constraint (of Cab1) the one-step conversion of FXIII-A to 
FXIII-A* (and the isopeptidase cleavage since no acceptor-donor cross-linked intermediate formation is required 
in this type of reaction) is facilitated. These observations present an interesting pharmaceutical possibility of 
engineering enzymes with multiple but quantitatively varying enzymatic capacities. Since FXIII-A possesses a 
transglutaminase, isopeptidase and also protein disulfide isomerase activity, it can serve as a model protein to 
generate variants with higher enzymatic efficiency than normal in one aspect but neutralized concerning the 
other activities27,28. A higher tlag observed for some calcium-binding mutants in the FXIII-A* generation assay is 
a representation of slow generation of the first active FXIII-A* species that can be attributed not just to thrombin 
cleavage but also to the underlying events which are responsible for the accessibility of active site cysteine (open-
ing of molecule) for incoming substrate molecule (Fig. 3c). Therefore, the calcium binding site residues critically 
govern the structural integrity of the core domain with a possible distal allosteric effect on FXIII-AP. Whether 
these variants alter the binding affinity of FXIII-A to thrombin or directly impede the cleavage reaction cannot 
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be ascertained from our data. The different endpoint-based assays between themselves revealed consistency only 
to a limited extent, i.e., all mutants reported consistently lower or similar activity status when compared to the 
wild type in all endpoint assays. However, quantitatively, these assays also revealed relative differences from one 
another for the mutants. For example, one mutation from Cab3 (D271K) and two from Cab2 (N347D, Q349D), 
reported consistently low levels in all these assays, indicating that the mutations distorted the substrate binding 
site (Fig. 2a–c). However, the extent of decrease in each assay was different, i.e., for the α2-antiplasmin assay all 
three mutants reported to have non-detectable levels, but for the other two assays variable detectable levels were 
observed which can be attributed to the fact that calcium binding sites spatially surround the catalytic site and 
are also proximal to the putative substrate binding sites. Their coordination subsequently plays a major role in the 
correct orientation of the substrate binding sites as can be seen in the transition state intermediate models17. Since 
the three assays are related to three different substrates, the relative impact on substrate affinity would depend 
on the extent to which each mutation affects the substrate binding site. As mentioned at the beginning of this 
paragraph, the disruption of Cab1 is also the rate-limiting step in FXIII-A activation which is highlighted by the 
increased response of the thrombin resistant FXIII-A subunit mutant (FXIII-A-R38A) in the generation assay to 
increased concentrations of calcium (Supplementary Fig. 3). The 20 mM calcium concentration appears to be the 
concentration barrier threshold above which calcium can coordinate Cab2 and Cab3 that eventually overpowers 
the zymogenic constraint associated with a coordinated Cab1. After the loss of the zymogenic constraint above 
this concentration, the rate of FXIII-A* generation follows an uninhibited exponential increase with increasing 
calcium concentrations (Supplementary Fig. 3).
FXIII conformational changes during activation are effected at the secondary structure level 
and are governed by ion coordination and its surface electrostatic potential. In several trans-
glutaminases cross-talk between calcium and other ions (depending on the physiological milieu) influences the 
activity status of the protein. In TGM3, calcium ion coordination induces the movement of a loop region that ena-
bles substrate access to the active site. Tighter coordination with magnesium ion instead of calcium keeps the loop 
in its inactive configuration. Therefore, the relative concentrations of calcium and magnesium act as a regula-
tory switch for transglutaminase activity in TGM329. FXIII-A protein which can be activated non-proteolytically 
by calcium only in the presence of supra-physiological levels of calcium (>50 mM) FXIII-A shows an inter-
esting behavior in the presence of sodium (Fig. 4)17. In the presence of high levels of sodium (~1 M NaCl), the 
non-proteolytic activation requirement of calcium goes down to physiological levels (2.5 mM). The principle 
behind the effect of sodium on the non-proteolytic calcium-induced activation of FXIII-A is very much different 
from that observed for TGM3 in the case of magnesium and calcium since unlike in TGM3, where binding of 
both magnesium and calcium is observed, in FXIII-A there is no actual coordination of sodium. Our MD sim-
ulations performed on FXIII-A monomer at physiological versus high concentration (supra-physiological) of 
sodium ions in the simulation cell reveals that higher levels of sodium without actual binding (or coordination) to 
FXIII, alters the FXIII-A surface electrostatic distribution (Fig. 4a). This event most likely disturbs the pKa (ion-
ization constant) of internal buried residues, thereby affecting intra-domain residue interactions and changing 
the local secondary structure, which results in subtle conformational changes. Very high concentrations of 1 M 
sodium likely alter the secondary structure of FXIII to the extent of overcoming the primary restraint induced 
by Cab1 bringing the molecule to the tipping point of activation but not activating it (Fig. 6). At this point, even 
physiological levels of calcium are adequate to non-proteolytically drive it from its zymogenic to activated con-
formation (heterotopic, the sequential and positive allosteric effect of sodium & calcium towards FXIII activa-
tion) (Fig. 6). Therefore, the extent and influence of calcium coordination on FXIII conformation also depends 
on the surface electrostatic state that in turn, is determined by the ionic strength/pH of FXIII´s solvent. The fact 
that ionic coordination alone does not influence protein conformation at the secondary structure level is further 
strengthened from our MD simulations in which we subjected only the core domain of the FXIII-A subunit to 
increasing concentrations of calcium (Fig. 4a). Again, as with high sodium concentrations, we observed a change 
in surface electrostatic potential with increasing calcium concentration (even though in the period of simulation, 
Figure 6. Effect of ancillary sodium ions towards generation of a pre-activation state of FXIII-A molecule. 
A cartoonist impression of the FXIII-A zymogenic state where no ions are influencing the structure followed 
by pre-activation state where the both the non-coordinating (assumed to be sodium in purple) as well as later 
coordinating ions (assumed to be calcium in yellow) influence the structure and conformation of FXIII-A 
molecule by altering its surface electrostatic properties. The last part of the figure depicts the fully activated 
molecule which is the final outcome of the coordination of the coordinating ions to its binding sites in a FXIII-A 
molecule that has already been moved from its zymogenic to a pre-activation state.
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no actual coordination was observed for calcium as well). Therefore, the activity status of FXIII-A is not only the 
result of the coordination of calcium ions to its three binding sites; it is the net impact of calcium coordination as 
well the response to ancillary solvent ion concentration surrounding the molecule. Even physiologically FXIII-A 
exists in different solvent environments with differing ionic concentrations. Intracellularly FXIII-A is present as 
a dimer, and since no thrombin is accessible intracellularly, any enzymatic role, e.g., crosslinking of cytoskeletal 
proteins like actin/myosin is possible only through non-proteolytic activation30–34. Intracellular non-proteolytic 
FXIII activation could be achieved either through sudden ion fluxes like calcium release from endoplasmic 
reticulum that might alter the levels of calcium to supra-physiological levels fit for non -proteolytic activation17. 
The other option might involve an increase in sodium concentration, which, as mentioned earlier, will support 
non-proteolytic activation even at low concentrations of calcium. FXIII-A has been reported in various bodily flu-
ids like placental fluid, tears, spinal fluid, etc. where it might have reparative roles30,35–38. If FXIII-A is considered 
as a therapeutic option for reparative processes related to these body fluids, knowledge of the subtle conforma-
tional changes brought about by the combination of ions in these fluids will help design easy to activate FXIII-A 
and with possibly a high specific activity.
energetic implications of calcium binding to fXiii explains why the activated form of fXiii-A is 
monomeric. The FXIII complex assembly and its dissociation in plasma primarily involve the formation and 
disruption of non-covalent hydrophobic interactions22. Intrinsic ion binding to proteins involves hydration ener-
gies, which are entropically driven39. Also, calcium binding to transglutaminases is reported to induce confor-
mational changes, as is observed in the crystal structures of activated forms of FXIII-A as well as TG215,22.These 
conformational changes result in a change of hydrophobic surface area while exposing the core domain active site. 
Therefore, these changes are associated with an increase in entropy as is evident from our thermodynamic profile 
observed upon the sequential binding of calcium at c-value = 20 (entropy-driven, ∆H > 0 to ∆H < 0) (Fig. 5). 
This also is evidence of in-cell FXIII-A activation taking place upon calcium binding at these concentrations. 
Interestingly, the proteins belonging to the family bearing the ‘transglutaminase core’ including FXIII-A, are not 
part of the EF-hand superfamily (a superfamily of proteins bearing two EF-hand units, each is made up of two 
helices connected with calcium binding loop), which characteristically are calcium-binding proteins (SCOPe 
database; http://scop.berkeley.edu/). Calcium binding to proteins lacking an EF-hand motif involves the coor-
dination of distal residues, made possible by changes in secondary structure/conformational changes as well as, 
major participation of a secondary ligand (like water) when required40. In our experiments with thrombin-cleaved 
rFXIII-A, the first step would be the saturation of Cab1. The ITC data suggest that the initial saturation event is 
highly spontaneous (∆G < 0), which is expected owing to the high affinity of FXIII-A towards calcium for Cab1 
(100 µM)3,17. The high K1 for Cab1 would ideally be enthalpically favorable since this strong ion binding would 
constrict the molecular motions by bringing about an order in the spatial secondary structure41–43.This however is 
not the case with FXIII-A in which we observe a ∆H > 0/∆S < 0 patterns at Cab1 saturation indicating that there 
is a secondary event, most likely the coordination of Cab2, happening concurrently, that’s directed towards the 
transient disruption of Cab1 resulting in an overall absorption of energy which is reflected in the ∆H > 0/∆S < 0 
patterns (Fig. 5d). Therefore, the first event cannot be independently thought of as binding of calcium at Cab1 
but rather the combined saturation of Cab1 and simultaneous coordination of Cab2 to the point of transient 
disruption of Cab1. Once the Cab1 is transiently disrupted, the molecule overcomes the zymogenic constraint 
and moves conformationally towards the open, active structure as a result of a gain of entropy. This part of the 
activation cycle can be considered as the second binding event where we observe a pattern of ∆H < 0/∆S < 0. The 
gain in entropy (∆∆S) for this second event is higher than that observed for the first event, although effectively 
∆G < 0, keeping the transformation to the activated form still favorable. At this point of time, the conformational 
changes taking place in FXIII-A have set into motion another event, which is the disruption of the zymogenic 
dimeric interface16. Major hydrophobic and non-covalent interactions between the opposing dimers are lost, 
resulting in (a) solvent-protected to a solvent-exposed state, and (b) exposure of Cab3. The third event in our 
thermodynamic cycle is the final coordination and saturation of Cab3, which is occurring simultaneously to 
the monomerization of the activated FXIII molecule. In this step, we observe a pattern of (∆H < 0, ∆S > 0) with 
the increase in entropy (∆∆S > 0), and release of heat (∆∆H«0) (Fig. 5d). This major increase itself represents a 
dissociative event combined with flexible inter-domain movements (of β-barrel domains). This event is aided by 
a major influx of water molecules in FXIII-A regions which were previously inaccessible to water (owing to the 
closed structural fold or the dimeric interface). The rise in entropy is the result of the enthalpic contribution of 
the final Cab3 saturation and dimer dissociation. This also keeps the overall free energy of the system negative 
(∆G < 0) favoring the final disruption of the dimeric interface to an open monomeric activated FXIII-A* form. 
The fast internal dynamics (conformational entropy, as a result of β-barrel domain movements), and slow internal 
dynamics (disruption of dimeric interface due to loss of hydrophobic interactions), leads to activation of a fully 
saturated FXIII-A* monomer, as the protein dissociates/solvate to a monomeric calcium saturated form (Fig. 7). 
One must, of course, remember that these events can occur in two different species, i.e., the dimeric FXIII-A2/
intracellular FXIII-A2 and the plasma heterotetramer FXIII-A2B2 complex. In the latter, there are two dissociative 
processes in action, i.e., the dissociation of the FXIII-A2 zymogen to its activated monomeric FXIII-A* form and 
the dissociation of the FXIII-B2 molecule from the complex. Our thermodynamic experiments do not involve the 
FXIII-B subunit since they are performed with rFXIII-A2 alone. However, both dissociative events most likely run 
simultaneously each contributing to the success of the other. Both are brought about by conformational changes 
upon calcium binding and influx of water molecule into previous hydrophobic cores formed by the respective 
folds of the protein and the pattern in which the zymogenic complex is assembled.
Studies on FXIII-A calcium binding explain the conformational changes occurring in the FXIII-A core 
domain, but how calcium binding contributes to the movement of the β-barrel domains was still unclear. A recent 
article shows that the first β-barrel domain protects the active site, and the second one is responsible for exposing 
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it42. Our data highlights how enthalpy-entropy compensation contributes to the generation and stabilization of a 
monomeric FXIII-A* activated molecule upon calcium ion binding. Since the final event in the thermodynamic 
cycle of FXIII-A activation is enthalpically driven instead of entropically (i.e. like the first two events) this suggests 
that the first two events introduce disorder into the molecule (conformational changes) while the third and last 
event stabilizes the final molecule resulting from this disorder/conformational change, i.e., dissociation into a 
monomeric state. Our thermodynamic analysis highlights the role of the influx of bulk solvent that in continua-
tion of the conformational changes induced by calcium binding enables the global domain movements observed 
during FXIII-A activation. At a structural level, we can observe these changes if we follow the conformation of 
the transition state models between the activated and zymogenic form of FXIII-A (Fig. 7). The β−1 and β-2 barrel 
domains in the zymogenic form are stabilized in through non-covalent bonds they form with the core domain 
that serves to shield the hydrophobic interior. The core domain is linearly linked to the β-barrel-1 domain by a 
hinge region which is unresolved in certain crystal structures of the zymogenic form like PDB ID: 1f13 because 
it is disordered and highly flexible. Therefore, barring the non-covalent attachment to the core domain, there is 
nothing preventing the β-barrel domains from moving flexibly over the hinge region. With the binding of cal-
cium, conformational changes occurring at the core domain disrupt the non- covalent association of core domain 
with the barrel domains. This primary disruption enables the entry of the solvent molecules to this conformation-
ally shielded region. Water influx further disrupts the β-barrel domain-core domain contacts, causing the β-barrel 
2 domain to fall over under its weight, pulling the β-barrel 1 domain along with it in which the connecting hinge 
region acts as the pivot. This falling over motion appears as the twisting and opening up of the β-barrel domain 
to expose the catalytic site. We can, therefore, suggest that the formation of active FXIII-A* species involves a 
thermodynamic process of “conditional conformational switching”29, which involves the essential participation 
of calcium and water molecules. In other words, the activation of FXIII-A is majorly driven by conformational 
entropy brought about by calcium binding. Since all reactions follow a common energetic purpose, i.e. to favor 
the energetically stable complex/conformation, dimeric zymogenic FXIII-A has Cab2 and Cab3 sites hidden 
which make the dimeric, calcium unbound form more favorable in the zymogenic state (Fig. 8). During activa-
tion, since regions previously hidden get exposed, calcium binding alters conformation as well stabilize the final 
monomeric FXIII-A* molecule by bringing structural order upon coordination and reducing the transiently gen-
erated randomness. This explains why a monomeric bound FXIII-A* would be favored over the activated form 
(Fig. 8). It also explains why the chelation of calcium from a non-proteolytically activated FXIII-A, will shift the 
equilibrium to reversibly generate the zymogenic-dimeric FXIII-A that can be re-activated. Recent experimental 
evidence has also shown that the activated form of FXIII-A is, in fact, monomeric and is capable of reconversion 
to its zymogenic dimeric state upon removal of calcium from the medium21. Ever since FXIII-A has been recog-
nized as a pharmaceutical candidate for inhibitor development, inhibitors have been designed primarily against 
the active site or the thrombin cleavage mechanism of this protein44–48. Our results suggest that two other areas 
of FXIII can potentially serve as regions against which inhibitors can be designed. The regions in and around the 
calcium binding sites belong to one group of potential candidates since they not only dictate the rate of activation 
but also the proper orientation of substrate binding sites. The other regions belong to the areas/cavities (next to 
β-barrel/core domain contacts) which allow the entry of bulk solvent upon the conformational changes induced 
by calcium binding. Neutralizing either of these candidate regions can potentially result in thermodynamically 
stabilizing intermediate conformational states of FXIII-A, thereby preventing the full activation of FXIII-A.
As a final commentary to this study, we would like to acknowledge some limitations of our study. Our 
work focusses on calcium binding without discriminating between proteolytic and non-proteolytic modes of 
Figure 7. Entry of bulk solvent induces movement of β-barrel domains. Figure illustrates the stepwise 
conformational changes occurring during the activation of FXIII-A. The figure(s) represent in successive 
order the zymogenic crystal structure of FXIII-A monomer, the third and sixth transition state intermediate 
models reported earlier and the fully activated structure of FXIII-A monomer. All structures are depicted in 
the ribbon format. The N-terminal beta sandwich domain has been hidden for the sake of clarity. The β-barrel 1 
and β-barrel 2 domains are coloured in green and blue respectively while the core domain is coloured grey. The 
hinge region of almost 20 amino acids is coloured red. The water solvation shell is depicted with blue circles. 
The movement of the β-barrel domains is depicted with black arrows. Contacts between the core and β-barrel 
domains are depicted with lightly coloured lines.
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activation16. A significant part of the work is based on transient transfections and in silico analysis performed on 
modeled structures. Similarly, the thermodynamic analyses are based on custom fitting models which themselves 
are built around hints from in silico experiments. We present this work to the readers as an exploratory character-
ization of individual calcium ion binding sites of FXIII-A. As future work, we will attempt to purify the mutants 
explored in this study to characterize them structurally/functionally in a pure, undiluted setting.
Methods
Transient heterologous expression of FXIII wild type and mutant variants. The human HEK293T 
cell line purchased from DMSZ (German Collection of Microorganisms and Cell Cultures) were cultured in high 
Glucose DMEM Invitrogen, supplemented with 10% v/v FBS (Invitrogen), 1% v/v Penicillin-Streptomycin anti-
biotics (Invitrogen) and 0.1% v/v Fungizone (Invitrogen), at 37 degrees in 5% CO2. All experiments were done 
on sub-cultured cells in logarithmic phase (below passage 20). Human FXIII-A cDNA, inserted into the cloning 
site of pDEST26TM vector (Invitrogen) was used as a wild-type construct for all the experiments. Site-directed 
mutagenesis was performed on the aforementioned construct, using GeneArt Site-directed mutagenesis system 
(Life Technologies). Mutagenesis was performed with the aim of either accelerating calcium ion binding (FXIII-A 
A264D, FXIII-A N347D, FXIII-A Q349D, FXIII-A A457D), or disrupting calcium ion binding to the respective 
site (FXIII-A N267K, FXIII-A D271K, FXIII-A D351K, FXIII-A E490K) based on our previous hypothesis16. One 
more mutant at the thrombin cleavage site (FXIII-A R38A) was generated to be resistant to thrombin-mediated 
activation. Although a total of 13 different residues contribute to calcium binding in the three FXIII-A calcium 
binding sites, we were successful in cloning and expressing only 8 of them. All primers were synthesized by 
MWG Eurofins (Eurofins genomics). All vector construct clones were completely sequenced and verified for the 
correct incorporation of mutations in-house. Wild-type FXIII-A DNA and mutated DNA were transfected into 
mammalian HEK293T cells for transient expression. Briefly, 2.7 × 105 cells were transfected with 3 µg of plasmid 
DNA along with 6 µl of transfection reagent lipofectamine 2000 (Invitrogen). Cultures were harvested 48 hours 
post-transfection, by performing intracellular lysis using mammalian native M-PER reagent (Thermo Fischer 
Figure 8. Derived Thermo-chemical Activation Cycle of Coagulation FXIII-A molecule in plasma. The free 
FXIII-A2 dimer, when devoid of any calcium possesses intact FXIII-AP and this species represents a low free 
energy stable form16. Cleavage of FXIII-AP by thrombin is followed by coordination and subsequent saturation 
of Cab1 and Cab2. Cab1 being spatially more accessible gets saturated faster and strongly than Cab2 yielding 
a low-energy, relatively stable state. Subsequently, the Cab2 coordination transiently disrupts Cab1 giving rise 
to a high-energy, unstable, transient state (event 1). The increasing saturation of Cab2 accompanied by the 
conformational changes directed by it result in the stabilization of unstable intermediate bringing down free 
energy. Meanwhile, slow disruption of the dimeric interface proceeds as the molecule proceeds towards full 
saturation (Cab3 gets exposed with the dimeric interface coming apart) (event 2). As the dimer loosens up, 
water molecules seep through and expose the dimeric interface further. Sharp movements of β-barrel domains 
as a consequence of calcium saturation, and movement of water molecules across the dimeric interface raise 
the entropy of the system, that finally culminate into dimer disruption, giving rise to monomeric, energy 
minimized, open active FXIII-A* species (event 3). Blue-grey object depict the N & C terminal of FXIII-A 
monomer, respectively. Molecule solvation shell is represented by dotted circle. Calcium ion saturation at Cab1, 
Cab2 and Cab3 is depicted by red, blue and green solid dots respectively. Black rod is the dimeric interface. 
Yellow star is the catalytic center. The three inset figure(s) demonstrate the secondary structure changes 
occurring during the course of activation explaining assembly (+) or disassembly (−) of calcium binding sites 
extracted from the Transition state intermediate models reported earlier16.
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Scientific Inc), containing 25 mM bicine, pH 7.6, supplemented with 0.1 mM PMSF for 10 minutes and centri-
fuged at 14,000 g for 5 minutes at 4 °C. Lysates were stored at −70 °C for later evaluation. Each transfection lot was 
accompanied with a positive control, i.e., HEK293T cells transfected with expression vector expressing eGFP. This 
lot helped us evaluate the success of the transfection as well as check for any endogenous FXIII/transglutaminase 
activity. Results for all assays performed on the transfection lysates were normalized accordingly.
Antigenic estimation of rFXIII-A by FXIII-A Western Blot Analyses. Intracellular lysate derived from 
transiently transfected HEK293T cells was verified for the antigenic presence of FXIII-A protein by western blot 
analysis. Intracellular lysate from transfected cells was quantified by BCA estimation (Pierce, Life technologies). 
The intracellular lysate was separated on 4–16% precast SDS PAGE (Biorad), followed by transfer to PVDF mem-
brane at 60 V for 90 minutes in cold room. The membrane was blocked for 1 hour at room temperature in blocking 
reagent (3% w/v BSA in PBS with 0.05% Tween-20). Subsequently, after a wash with PBS-Tween (0.05%), the 
membrane was incubated for 1 h at room temperature in Primary antibody (1 µg/mL) (Rabbit-anti human Factor 
XIII-A polyclonal antibody, Thermo Fischer Scientific Inc) with mild shaking. After washing thrice in PBS-Tween 
(0.05%), the membrane was incubated for 1 h at room temperature in HRP tagged Secondary antibody (50 ng/
mL) (Anti-Rabbit HRP, Thermo Fischer Scientific Inc). Finally, the membrane was washed thrice in PBS-Tween 
and PBS, respectively. Chemiluminescent signal quantification, Image acquisition (ChemiDoc MP, Bio-Rad) and 
densitometric evaluation of signal were performed on Image lab Software (Bio-Rad) version 4.1. Using known 
amounts of recombinant FXIII-A (positive control), the percentage antigenicity and absolute quantity of anti-
genically active FXIII-A was calculated in transfected samples based on the chemiluminescent intensity of the 
signal. The antigenic levels determined by densitometry were confirmed with a commercial sandwich ELISA 
(AssayMax). The antigenic levels were used in combination with activity levels from photometric assay to calcu-
late the specific activity of the individual samples.
FXIII activity determination by biochemical end-point assays. Photometric assay. Intracellular 
lysates (Wild type; Mutants), were 6X concentrated using Amicon filters (30 kDa cut-off) (Merck Millipore) for 
the evaluation of FXIII activity with a kinetic photometric assay (Berichrom, Siemens, Germany). Briefly, sam-
ples were activated in the presence of thrombin and calcium, at 37 °C, transglutaminase activity of FXIII-A was 
measured indirectly by measuring released indicator, i.e., Ammonia (Abs 340 nm). A decrease in absorbance 
is directly proportional to FXIII-A transglutaminase activity in the samples49. The assay was performed on the 
Behring Coagulation System® (BCS) (Dade Behring, Marburg, Germany). All the experiments were performed 
in duplicates, with three sets of transfections to ensure reproducibility.
Pentylamine incorporation assay. The activity of intracellular lysates of recombinant factor XIII (rFXIII) 
Wild type, Mutants and a negative control was determined based on a pentylamine incorporation assay as 
described previously50. Briefly, microtiter plates were coated with 80 µg/mL human fibrinogen (Enzyme Research 
Laboratories, UK) at 37 °C for 1 hour, then blocked with 1% BSA overnight at 4 °C. Plates were incubated 
with duplicates of 10 μL lysate, 0.27 μM 5-(Biotinamido) pentylamine (Thermo Fisher Scientific Inc), 1 U/mL 
human thrombin (Calbiochem, Merck KGaA), 100 μM Dithiothreitol (Sigma), and 1 mM CaCl2. Incorporation 
of 5-(Biotinamido) pentylamine was stopped with 133 mM EDTA after 0 or 30 minutes. Cross-linking of the 
5-(biotinamido) pentylamine into the fibrin by recombinant FXIII was detected using streptavidin-alkaline 
phosphatase (Life Technologies) and p-Nitrophenyl phosphate (Sigma). Plates were measured at OD 405 nm 
in a Powerwave Bio-Tek multiwell plate reader (Winooski, USA). Optical density (OD) values at time 0 were 
subtracted from the 30-minute readings for each lysate to remove background and a standard curve of known 
concentrations of FXIII were used to extrapolate activity of rFXIII in each lysate.
Determination of protein activity by α2-antiplasmin incorporation. The activity of intracellular lysates containing 
recombinant factor XIII (rFXIII) wild type, mutants, and a negative control was also assayed by α2-antiplasmin 
incorporation, based on a method previously described51. Briefly, microtiter plates were coated with 80 µg/mL 
human fibrinogen (Enzyme Research Laboratories, UK) at 37 °C for 1 hour, then blocked with 1% BSA overnight 
at 4 °C. Plates were then treated in duplicate with 10 μL lysate, 10 µg/mL α2-antiplasmin (Calbiochem), 1 U/mL 
human thrombin, 0.1 mM DTT, and 10 mM CaCl2. Incorporation of α2-antiplasmin was stopped with 133 mM 
EDTA after 0 or 60 minutes. Cross-linking of the α2-antiplasmin into the fibrin by rFXIII was detected using goat 
anti-human α2-antiplasmin antibody with a horse-radish peroxidase conjugate (Enzyme Research Laboratories) 
and 1, 2-diaminobenzene o-phenylenediamine (OPD; Dako). Plates were measured at 490 nm in a multi-well 
plate reader (Bio-Tek). OD values at time 0 were subtracted from the 60-minute readings for each lysate to remove 
background and a standard curve of known concentrations of FXIII were used to extrapolate activity of rFXIII 
in each lysate.
fXiii activity determination by a continuous fXiii-A* generation assay. Activated FXIII-A 
(FXIII-A*) generation was triggered by tissue factor/phospholipids (TF/PL), and FXIII-A* isopeptidase activity 
was measured using the fluorogenic substrate A101 (Zedira, Darmstadt, Germany) in a Safire microtiter plate 
reader (Tecan, Crailsheim, Germany)26. Twenty-five microliters FXIII-deficient plasma (deficient for FXIII-A2 
and FXIII-B2; Haemochrom Diagnostica GmbH, Essen, Germany) spiked rFXIII-A2 mutants (equal amount of 
crude samples based on antigenicity) were incubated with 35 μL reagent solution (5 μL 100 mM glycine methyl 
ester, 5 μL 2 mM fluorogenic FXIII-A* substrate, 10 μL Innovin (recombinant TF; Dade Behring, IL, USA) diluted 
1:700 in phospholipids (PTT reagent kit, Roche,USA) and 15 μL HBS (20 mM Hepes, 150 mM NaCl)/0.1% serum 
albumin pH 7.5. The reaction was started with 40 μL HBS pH 7.5 containing 25 mM CaCl2. For the throm-
bin resistant mutant FXIII-A-R38A, increasing amounts of calcium (25 mM, 50 mM, 100 mM, and 200 mM) in 
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HBS pH 7.5 were used. Fluorescence was measured over 1 hour at excitation wavelength = 330 nm and emission 
wavelength = 430 nm in kinetic mode with data acquisition 2 times per minute. All the experiments were per-
formed in duplicates, with three sets of transfections to ensure reproducibility. Human standard plasma (Siemens 
Healthcare, Erlangen, Germany) was used as an internal assay control.
Three parameters (further explained in the statistical analysis section) were obtained for each variant and the 
wild type from the FXIII-A* continuous generation curve:
 (A) Rate of FXIII-A* generation/maximal rate (µ; expressed as ∆R.F.U/min) which represents the rate of 
conformational change between the zymogenic and activated forms. The transglutaminase crosslinking 
reaction is a two-step reaction (a ping-pong mechanism), in which two substrates sequentially accesses 
the active site to first form intermediates and then get crosslinked to each other22,25. Since the continu-
ous generation assay relies on the isopeptidase activity which involves a singular cleavage/hydrolysis of a 
quencher attached to the substrate peptide immediately post the formation of the activated FXIII-A*, it is 
more reflective of the change in conformation between the zymogenic and activated FXIII-A forms than 
any end-point assays. Theoretically, both continuous-generation assay and end-point activity assay should 
show correlation, but that might not be the case for mutant variants, especially those that alter substrate 
binding sites.
 (B) The tlag is the time required for the activation of FXIII-A by thrombin (in plasma background), in the 
generation assay. Since in generation assay, the activation process is initiated by Innovin, a recombinant 
tissue factor and which is upstream to the thrombin cleavage of FXIII-A in the coagulation pathway, there 
is always some time lag before the first signal of activated FXIII-A* can be recorded. Any delay or faster 
tlag might signify differences in thrombin cleavage of FXIII-A.
 (C) The tmax is the time taken to reach the maximal rate µ.
(Note: An illustration of the generation assay curve along with a small commentary is provided in 
Supplementary Fig. 2 to help the reader understand the assay better).
Mapping substrate binding sites on fXiii-A subunit activation transition state intermediate 
models. We used FXIII-A subunit activation transition state intermediate models we had earlier generated 
and reported, to study the changes in the substrate binding regions as the FXIII-A molecule unfolds from its 
closed zymogenic state to its open fully activated state during the process of activation16.Three major putative 
substrate binding regions i.e. fibrinogen, BAPA and α-2 antiplasmin were considered since the endpoint FXIII 
activity assays dealt with these substrates. These binding regions had been determined by rigid docking studies 
we had earlier conducted and reported for fibrinogen and α-2 antiplasmin52.The putative BAPA binding region(s) 
were predicted by docking the structural coordinates of BAPA [5-(Biotinamido) pentylamine; Pubchem ID: 
CID 83906] that were downloaded from Pubchem database (as an SDF file and later converted to a PDB file on 
YASARA), onto the activated FXIII-A crystal structure (PDB ID: 4kty) downloaded from the protein database. 
Semi-flexible docking was performed with the Autodock function embedded in YASARA52.Finally these binding 
regions were mapped and highlighted on the FXIII-A subunit activation transition state intermediate models.
Molecular dynamic simulation of FXIII-A at different ionic concentrations. The effect of increas-
ing ion concentration on the structure of FXIII-A subunit was studied by running plain Molecular dynamics 
(MD) simulation the zymogenic human FXIII-A2 crystal structure (PDB ID: 1f13; 2.1 Å resolution) and only 
the core domain of FXIII-A subunit (isolated from the PDB ID: 1f13 and consisting of the amino acids between 
183–515 residues) on the YASARA Structure package version 13.11.1 platform53,54. Gaps or unresolved regions 
within the crystal structure(s) were modelled on the FREAD loop modelling server (http://opig.stats.ox.ac.uk/
webapps/fread/)55, e.g., the PDB file 1f13 that has missing regions at the thrombin cleavage site Arg37-Gly38 was 
submitted to the server under default parameters and with the starting and ending residue of the missing region 
specified. The final gap resolved structure was chosen from the output file based on scores that were a combina-
tion of all backbone atom anchor match RMSD (corresponds to the base structure) and all backbone atom loop 
match RMSD (corresponds to the loop structure). The PDB files were initially subjected to a 500 ps refinement 
MD simulation run that imposes the YAMBER3 force field parameters in YASARA in order to remove steric 
clashes and improve rotamer geometry53. The file with the lowest energy in the simulation trajectory was chosen 
for conducting further simulations. Simulations were performed with the md_sim macro embedded in YASARA. 
The macro was modified for running simulations at different ionic concentrations. Briefly, a simulation cell with 
periodic boundaries and 20 Å minimum distances to protein atoms was employed with explicit solvent. The 
AMBER03 force field, NPT ensemble was used with long range PME potential and a cut-off of 7.86Å56. Hydrogen 
bond networks were optimized using the method of Hooft and co-workers57. The simulation cell was filled with 
water at a density of 0.997 g/mL and a maximum sum of all bumps per water of 1.0 Å. Most importantly, the sim-
ulation cell net charge was neutralized with different NaCl and CaCl2 concentrations. While the full zymogenic 
dimeric structure was simulated at 150 mM and 1 M NaCl, the core domain was simulated at 5 mM, 10 mM, 
50 mM, and 100 mM CaCl2. The entire system was energy minimized by steepest descent to remove conforma-
tion stress within the structure, followed by simulated annealing minimization until convergence was achieved. 
The MD simulation was performed at 298 K. Simulations for all structures at all concentrations were run for a 
minimum of 100 ns after equilibration was achieved. Secondary structure content during the MD simulations was 
visualized using the md_analyzesecstr macro output embedded in YASARA on R. Structural image visualization, 
analysis, and rendering were done with YASARA 13.11.1 and Chimera version 1.10.254,58. Electrostatic surface 
potential was calculated and graphically depicted using the Adaptive Poisson-Boltzmann Solver integrated within 
YASARA59. The inter-residue interaction or Residue interaction network (RIN) within a structure was visualized 
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by submitting the PDB file corresponding to that structure (usually the 100 ns simulation snapshot for all sim-
ulated structures in this study) to the RING 2.0 server (http://protein.bio.unipd.it/ring/)60. The server identifies 
covalent and non-covalent bonds in protein structures, including π–π stacking and π–cation interactions using 
a complex empirical re-parameterization of distance thresholds performed on the entire submitted PDB file. The 
output is in the form of a colour coded point and connector network pattern. The colour codes are explained in 
the inset diagram for all network pattern outputs.
Conservation of calcium binding sites within FXIII-A subunit. The conservation of the calcium binding 
site residues within the FXIII-A subunit were analyzed on the ConSurf server (http://consurf.tau.ac.il/2016/)61 which is 
a bioinformatics tool for estimating the evolutionary conservation of amino/nucleic acid positions in a protein/DNA/
RNA molecule based on the phylogenetic relations between homologous sequences61. The degree to which an amino 
(or nucleic) acid position is evolutionarily conserved (i.e., its evolutionary rate) is strongly dependent on its structural 
and functional importance. The FXIII-A sequence from UniProt (ID: P00488) was submitted to this server under 
default conditions (Homolog search algorithm: HMMER; E value cut off at 0.0001; Proteins database: UNIREF-90; 
Alignment method: MAFFT-L-INS-i; Calculation method: Bayesian; Evolutionary substitution model: Best model) 
but with higher number (n = 5) iterations. The resulting alignment output was viewed on the Jalview alignment viewer. 
The structural conservation of the calcium binding sites was evaluated by structurally aligning all human transglutam-
inase structures, including FXIII-A subunit using the Multiseq tool embedded in VMD62. All biophysical structures 
for FXIII-A subunit (PDB ID: 1f13), TG2 (PDB ID: 4pyg) and TG3 (PDB ID: 1nuf) that are currently resolved and 
available were downloaded from the protein database for this purpose15,29,63. The remaining transglutaminases with 
no known structures were modeled on I-TASSER modeling and threading server64. The sequences of these transglu-
taminases (extracted from the Uniprot database) were submitted to the I-TASSER server under default conditions. 
The highest scoring (best C-score) model among the output files was chosen for multiple alignments (Supplementary 
Fig. 9a–d). Post alignment, a structure-based phylogenetic tree was generated using delta QH values, which is a meas-
ure of structural homology. Subjects closer to each other on this tree are structurally similar.
thermodynamic analyses of calcium binding to fXiii-A by isothermal titration calorime-
try. Isothermal titration calorimetry experiments were carried out on a MicroCal200 microcalorimeter 
(Malvern Panalytical, UK). The reference cell was filled with Autoclaved MiliQ water. The rFXIII-A2 (expressed 
in-house in Yeast expression system) in the sample cell was titrated against calcium concentrations. The sample 
(rFXIII-A2) was re-suspended in 20 mM Tris pH 8.2 before titration. In principle, the titrations were performed 
based on the c-value (concentration of calcium in syringe/concentration of sample rFXIII-A2 in the cell). Since 
plasma FXIII and calcium ion concentration are 2 mg/L (an effective molar concentration of 0.0125 µM) and 
2.5 mM respectively, the c-value for mimicking a plasmatic environment will be almost 200,000 which is beyond 
the sensitivity of ITC65–67. Hence, titrations were performed at a high c-value as 25,000; and a standard c-value 
of 2067. For each of the conditions, titrations were performed in the same buffer (20 mM Tris, pH 8.2), unless 
stated otherwise. For c-value = 20, 1.25 mM of rFXIII-A2 was titrated against 25 mM CaCl2 (with 13.8U thrombin 
(Sigma) in the sample cell). The titration involved 19 injections (12 × 2, 0.4 × 6, each injection spaced by 120 s). 
To ensure complete saturation, the reaction was continued with a further 19 injections (12 × 2, 0.4 × 6, each 
injection spaced by 120 s). Both the resulting isotherms were concatenated with CONCAT tool provided with 
the Origin software (version 7.0) (OriginLab)68. For c-value = 25,000; 1 × 10−3 mM rFXIII-A2, activated by 2U of 
thrombin (Sigma) was titrated against 25 mM calcium. The titration was performed for 19 injections 2 µL each, 
spaced at 150 s, to reach full saturation, the reaction proceeded with further 19 injections (0.4 µL each, spaced 
at 150 s) and the titrations were concatenated with CONCAT tool provided with the Origin software (version 
7.0). All the experiments were performed in the same buffer (20 mM Tris, pH 8.2), at 30 degrees with the stirring 
speed set to 750 rpm, at low feedback. For each experiment, thrombin was added before the start of the reaction; 
hence rFXIII-A2 was incubated with thrombin, in the absence of calcium for the period of pre-titration delay. To 
account for the heat of dilution, we performed blank experiments under the same conditions without rFXIII-A2 in 
the sample cell (Thrombin in cell titrated against CaCl2 in the syringe). Peak integration was done in the software 
Origin 7.0. For thermodynamic analysis, initially, we used Origin software, for single set of binding model, in 
order to observe the binding as a global fit. The parameter Kd was approximated around 100 µM based on earlier 
reports, was set as non-varying parameter for sequential binding site model with 3 set of binding sites (Even for 
sequential binding site model, it is advisable to have initial guesses for n, K and ∆H)3,69. (The K1 was used as a 
standalone non-varying parameter for the further fitting of data in all fitting exercises). Subsequently, heat capac-
ity changes for each injection were calculated based on the algorithms followed by Origin software, as well as stoi-
chiometric equilibria model (described below) in Affinimeter (https://www.affinimeter.com)70 and the process was 
iterated until no further significant improvement in fit were observed. Individual heat-signatures were derived 
from the energy definitions upon each binding after model fitting also by using Affinimeter. The corresponding 
thermodynamic parameters were calculated according to the equation ln(1/Kd) = (∆H-T∆S)/RT. Additionally, 
titrations were performed at 1 µM and 0.4 µM FXIII-A2, with ligand (calcium ion) concentration of 12 µM and 
14 µM respectively (for c-values 12 and 35) (data not shown), and no binding was observed in these titrations. 
The titrations were first simulated in Affinimeter with the aforementioned c-values & fitting was simulated to the 
following custom design model, using the model-builder approach on Affinimeter app to dissect the contribution 
of individual species generated during the course of FXIII-A activation, following the hypothetical equation:
+ + +AM A M A A M A M A1 1 1 1 1 1 2 1 1 3  
where M is FXIII-A2, A is calcium ion.
The final data was interpret based on fitting exercises performed using Affinimeter.
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Statistical analysis. Statistical analysis was performed using R69. For endpoint assays, mean values were 
compared (to the wild type) by Student’s two-tailed t-test. In the generation assays, data was analyzed based on 
growth-curve analyses, with the slope of the curve (µ) representing the growth rate. Data were fit using R-package 
“Grofit”, based on the dose-response relationship71. Non-parametric spline estimation was done to fit the data, 
and to obtain the characteristic parameters lag phase (tlag), maximal growth rate (µ), time of maximal growth rate 
(tmax), maximal growth (A) and area under the growth for each single growth curve.
The function follows the following parameterization:
λ= − − +∗ ∗ ∗µy t A t( ) exp[ exp( exp(1)/A ( ) 1)]
Abbreviations: lag phase (tlag): λ maximal growth rate (rate of activation): µ, Area under curve: A, and time 
of observation: t
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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